Common Contracts

2 similar Investor Rights Agreement contracts by Regentis Biomaterials Ltd.

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT
Investor Rights Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) made as of the 5th day of February 2016, by and among Regentis Biomaterials Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 513585240, located at 12 Ha’ilan street, Northern Industrial Zone, P.O.B 260, Or Akiva 30600, Israel(the “Company”), the individuals and entities identified in Schedule 1 attached hereto (collectively, the “Series A Preferred Holders”), the individuals and entities identified in Schedule 2 attached hereto ( the “Series B Preferred Holders”); the individuals and entities identified in Schedule 3 attached hereto (collectively, the “Series C Preferred Holders”), the individuals and entities identified in Schedule 4 attached hereto ( the “Series D Preferred Holders” and together with the Series A Preferred Holders and the Series B Preferred, Series C Preferred the “Preferred Holders”); The Company, the Series A Preferred Holders Series B Preferred Holders the

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT
Investor Rights Agreement • November 4th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) made as of the 5th day of February 2016, by and among Regentis Biomaterials Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 513585240, located at 12 Ha’ilan street, Northern Industrial Zone, P.O.B 260, Or Akiva 30600, Israel(the “Company”), the individuals and entities identified in Schedule 1 attached hereto (collectively, the “Series A Preferred Holders”), the individuals and entities identified in Schedule 2 attached hereto ( the “Series B Preferred Holders”); the individuals and entities identified in Schedule 3 attached hereto (collectively, the “Series C Preferred Holders”), the individuals and entities identified in Schedule 4 attached hereto ( the “Series D Preferred Holders” and together with the Series A Preferred Holders and the Series B Preferred, Series C Preferred the “Preferred Holders”); The Company, the Series A Preferred Holders Series B Preferred Holders the